These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34750815)

  • 21. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
    Woloshin S; Kesselheim AS
    JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531
    [No Abstract]   [Full Text] [Related]  

  • 22. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 23. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
    Gleason A; Ayton S; Bush AI
    Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
    [No Abstract]   [Full Text] [Related]  

  • 24. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aducanumab: First Approval.
    Dhillon S
    Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA Drug Approval and the Ethics of Desperation.
    Largent EA; Peterson A; Lynch HF
    JAMA Intern Med; 2021 Dec; 181(12):1555-1556. PubMed ID: 34694325
    [No Abstract]   [Full Text] [Related]  

  • 28. Aducanumab and the FDA - where are we now?
    Fillit H; Green A
    Nat Rev Neurol; 2021 Mar; 17(3):129-130. PubMed ID: 33442064
    [No Abstract]   [Full Text] [Related]  

  • 29. Making the Case for Accelerated Withdrawal of Aducanumab.
    Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
    J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aducanumab for Alzheimer's disease?
    Walsh S; Merrick R; Milne R; Brayne C
    BMJ; 2021 Jul; 374():n1682. PubMed ID: 34226181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can we learn lessons from the FDA's approval of aducanumab?
    Liu KY; Howard R
    Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA.
    Karlawish J; Grill JD
    Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383
    [No Abstract]   [Full Text] [Related]  

  • 33. Challenges with new treatments for Alzheimer disease: Accelerated approval of aducanumab in the United States raises questions.
    Hogan D; Frank C
    Can Fam Physician; 2023 Mar; 69(3):160-161. PubMed ID: 36944523
    [No Abstract]   [Full Text] [Related]  

  • 34. Aducanumab, amyloid, and culture wars.
    Iliffe S; Manthorpe J
    BMJ; 2021 Aug; 374():n2038. PubMed ID: 34413026
    [No Abstract]   [Full Text] [Related]  

  • 35. Questions EMERGE as Biogen claims aducanumab turnaround.
    Howard R; Liu KY
    Nat Rev Neurol; 2020 Feb; 16(2):63-64. PubMed ID: 31784690
    [No Abstract]   [Full Text] [Related]  

  • 36. A carte blanche approval in Alzheimer's.
    Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862
    [No Abstract]   [Full Text] [Related]  

  • 37. ENGAGE and EMERGE: Truth and consequences?
    Kuller LH; Lopez OL
    Alzheimers Dement; 2021 Apr; 17(4):692-695. PubMed ID: 33656288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US FDA defends approval of Alzheimer's disease drug.
    Jaffe S
    Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382
    [No Abstract]   [Full Text] [Related]  

  • 39. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

  • 40. The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.
    de la Torre JC; Gonzalez-Lima F
    J Alzheimers Dis; 2021; 82(3):881-882. PubMed ID: 34250943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.